DALLAS, November 10, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clinical data for LP-184 (zirdafulven) in patients with recurrent GBM. LP-184 is being developed as STAR-001 for central nervous system (CNS) cancers. The paper appears in the October 2026 issue of Cancer Research Communications, a peer-reviewed journal of the American Association f
Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.
DALLAS, October 08, 2026--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.
DALLAS, October 07, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC™ trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is now open to
Investor Brand Network Press Release.
DALLAS, September 29, 2026--Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern", the "Company" or "we"), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.09 per share (or pre-funded warrant in lieu thereof) i
Investor Brand Network Press Release.
BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.
Detailed price information for Bayerische Motoren Werke ADR (BMWYY) from The Globe and Mail including charting and trades.
DALLAS, September 17, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeu
October 3 Southeast Asia launch will add distribution reaching approximately 68 million householdsNEW YORK CITY, NY / ACCESS Newswire / September 5, 2026 / , the 18-year media brand serving public companies and companies aspiring to enter the public markets, today announced its latest broadcast airing at 6:30 PM ET across Bloomberg Television in the United States, Latin America and the Middle East and North Africa (MENA).The program features executive interviews and corporate updates from Lanter
Motley Fool Press Release.
This is the newest page. Registered accounts read further back.